-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB:MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Since its formation, Mindset has the goal of taking drug discovery from known psychedelics within the tryptamine drug class (such as psilocybin and DMT) to expand a portfolio of drug candidates for neuropsychiatric conditions.
This time, Mindset's scientists combined a fragment-based drug discovery (FBDD) method with a highly focused medicinal chemistry strategy to design and develop three new small molecule non-tryptamine scaffolds, introduced as Families 6, 7 and 8.
The company has already filed provisional patent applications on them. The new drug families include approximately forty novel drug-like lead compounds, which were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies.
Preclinical screening has shown a significant boost in receptor functional potency and selectivity and in the case of some compounds, a greater central nervous system (CNS) penetration, oral activity and efficacy.
CEO James Lanthier stated: "Mindset's leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field."
Photo by Matheus Ferrero on Unsplash
Mindset Pharma Inc. (OTCQB:MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Mindset Pharma Inc.(场外交易代码:MSSTF), 一家生产精神疾病迷幻和非迷幻药物的公司最近发现另外三个高度新颖的非色胺迷幻化合物家族。
Since its formation, Mindset has the goal of taking drug discovery from known psychedelics within the tryptamine drug class (such as psilocybin and DMT) to expand a portfolio of drug candidates for neuropsychiatric conditions.
自成立以来,Mindset的目标是从色胺类药物(如裸盖菇素和DMT)中获得已知迷幻剂的药物发现,以扩大其产品组合候选药物治疗神经精神疾病。
This time, Mindset's scientists combined a fragment-based drug discovery (FBDD) method with a highly focused medicinal chemistry strategy to design and develop three new small molecule non-tryptamine scaffolds, introduced as Families 6, 7 and 8.
这一次,Mindset的科学家将基于片段的药物发现(FBDD)方法与高度集中的药物化学策略相结合,设计和开发了三种新的小分子非色胺支架,介绍如下家庭6、7和8。
The company has already filed provisional patent applications on them. The new drug families include approximately forty novel drug-like lead compounds, which were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies.
该公司已经提交了临时专利申请在他们身上。新的药物家族包括大约40种新的类药物先导化合物,它们是在体外羟色胺(5-HT)亚型受体和体外吸收、分布、代谢和排泄(ADME)研究中合成和评价的。
Preclinical screening has shown a significant boost in receptor functional potency and selectivity and in the case of some compounds, a greater central nervous system (CNS) penetration, oral activity and efficacy.
临床前筛选显示,受体功能效力和选择性显著提高,在某些化合物的情况下,更大的中枢神经系统(CNS)渗透、口服活动和疗效。
CEO James Lanthier stated: "Mindset's leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field."
首席执行官詹姆斯·兰蒂耶声明说:“Mindset的领先药物发现引擎继续产生创新,有可能帮助世界各地患有神经精神和神经障碍的患者。新家族6、7和8的发现表明,我们致力于扩大我们的研发,并加强我们的知识产权(IP)组合,超越迷幻领域的经典色胺。”
Photo by Matheus Ferrero on Unsplash
马修斯·费雷罗在Unspash上的照片
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧